6533b871fe1ef96bd12d26dd

RESEARCH PRODUCT

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

M. TurazzaNicla La VerdeStefania GoriFilippo AlongiMatteo ValerioAntonio FrassoldatiAntonio RussoLucio LaudadioOrnella GarroneAlessandro InnoLuigi CavannaAlessandra FabiVita LeonardiEmiliana TarenziJennifer FogliettaGianluigi LunardiElisabetta CretellaPatrizia ViciF. MarchettiDaniele GalantiS. MorosoSandro BarniFabio Puglisi

subject

Adult0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSocio-culturaleBreast NeoplasmsLapatinibTreatment experiencedRadiosurgerySRS03 medical and health sciences0302 clinical medicineBreast cancerTrastuzumabInternal medicineHER2 Positive Breast CancerBiomarkers TumormedicineHumansAgedRetrospective Studiesbusiness.industryLapatinibTrastuzumabMiddle AgedWBRTPrognosismedicine.diseaseCombined Modality TherapyConfidence intervalSurvival RateRadiation therapyLapatinib SRS Surgery Trastuzumab WBRT030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisLapatinib; SRS; Surgery; Trastuzumab; WBRTSurgeryFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drug

description

There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2Data of 154 patients were retrospectively collected at 14 Italian institutions through a specifically designed database.Median overall survival (OS) was 24.5 months. Patients receiving surgery/stereotactic radiosurgery experienced longer OS compared to those receiving whole-brain radiotherapy or no treatment (33.5 vs. 11.4 months; hazard ratio = 0.34; 95% confidence interval, 0.22-0.52; P .001). Interestingly, whole-brain radiotherapy did not improve OS compared to no treatment (11.4 vs. 9.8 months; hazard ratio = 0.99; 95% confidence interval, 0.62-1.62; P = .99). HER2-targeted therapy was associated with better OS compared to systemic therapy without HER2-targeted therapy or no systemic therapy (27.5 vs. 5.4 months; hazard ratio = 0.26; 95% confidence interval, 0.17-0.41; P .001). At multivariate analysis stratified by local treatments, systemic therapy, Karnofsky performance status, and neurologic symptoms significantly affected OS. Age, number of BM, steroid therapy, number of previous lines of systemic therapy, status of extracranial disease, and period of diagnosis had no significant impact on OS.Patients with BM from HER2

yearjournalcountryeditionlanguage
2019-01-01Clinical Breast Cancer
https://doi.org/10.1016/j.clbc.2019.05.006